Bibliografia

 

• Abrahamsen B. Are long-term bisphosphonate users a reality? Dose years for current bisphosphonate users assessed using the danish national prescription database. Osteoporos Int. 2013 Jan; 24(1):369-72.
• Adami S, San Martin J, Muñoz-Torres M, Econs MJ, Xie L, Dalsky GP et al. Effect of raloxifene after recombinant teriparatide [hPTH(1–34)] treatment in postmenopausal women with osteoporosis. Osteoporos Int 2008; 19:87-94.
• Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348:1535-41.
• Black DM, Schwartz AV, Ensrud KE, FLEX Research Group, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006; 296:2927-38.
• Eastell R, Hannon RA, Wenderoth D, Rodriguez-Moreno J, Sawicki A. Effect of stopping risedronate after long-term treatment on bone turnover. J Clin Endocrinol Metab. 2011; 96:3367-73.
• Grima DT, Papaioannou A, Airia P, Ioannidis G, Adachi JD. Adverse events, bone mineral density and discontinuation associated with generic alendronate among postmenopausal women previously tolerant of brand alendronate: a retrospective cohort study. BMC Musculoskelet Disord. 2010 Apr 14;11:68.
• Netelenbos JC, Geusens PP, Ypma G, Buijs SJ. Adherence and profile of non-persistence in patients treated for osteoporosis-a large-scale, long-term retrospective study in The Netherlands. Osteoporos Int. 2011 May; 22(5):1537-46.
• Penning-van Beest FJ, Erkens JA, Olson M, Herings RM. Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int. 2008 Apr; 19(4):511-7.
• Piscitelli P, Iolascon G, Gimigliano F, Muratore M, Camboa P, Borgia O, Forcina B, Fitto F, Robaud V, Termini G, Rini GB, Gianicolo E, Faino A, Rossini M, Adami S, Angeli A, Distante A, Gatto S, Gimigliano R, Guida G; SIOMMMS study group; CERSUM research group. Incidence and costs of hip fractures compared to acute myocardial infarction in the Italian population: a 4-year survey. Osteoporos Int. 2007 Feb; 18(2):211-9.
• Ravn P, Christensen JO, Baumann M, Clemmesen B. Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: prediction of bone mass changes during treatment. Bone. 1998; 22:559-64.
• Rossini M, Bianchi G, Di Munno O, Giannini S, Minisola S, Sinigaglia L, Adami S; Treatment of Osteoporosis in clinical Practice (TOP) Study Group. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int. 2006; 17(6):914-21.
• Schwartz AV, Bauer DC, Cummings SR, FLEX Research Group, et al. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res. 2010; 25:976-82.
• Sheehy O, Kindundu CM, Barbeau M, LeLorier J. Differences in persistence among different weekly oral bisphosphonate medications. Osteoporos Int. 2009 Aug; 20(8):1369-76.
• Whitaker M, Guo J, Kehoe T, Benson G. Bisphosphonates for osteoporosis-Where do we go from here? N Engl J Med. 2012; 366:2048-51.

 

 

 

 

 

<< Torna alla Home